SGMO: Summary for Sangamo Therapeutics, Inc. - Yahoo Finance

UK Markets close in 7 hrs 33 mins

Sangamo Therapeutics, Inc. (SGMO)


NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
4.75+0.45 (+10.47%)
At close: 4:00PM EDT
People also watch
SGENALNYZIOPPGNXHALO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous close4.30
Open4.40
Bid3.25 x 100
Ask5.35 x 700
Day's range4.35 - 4.80
52-week range2.65 - 7.60
Volume1,185,039
Avg. volume579,696
Market cap336.66M
Beta3.99
PE ratio (TTM)-4.68
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • PR Newswire12 hours ago

    Sangamo Announces The Retirement Of Its Founder And Genome Editing Pioneer Edward Lanphier From The Board Of Directors

    RICHMOND, Calif., April 25, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO), the leader in therapeutic genome editing, today announced that its founder and Chairman Edward Lanphier is not standing for re-election as a director nominee of Sangamo's Board of Directors at the 2017 Annual Meeting of Stockholders. The announcement comes after a year-long transition period following Lanphier's retirement from Sangamo management in June 2016 after 21 years as President and Chief Executive Officer. "Under Edward's leadership, Sangamo pioneered the field of genome editing with the development of ground-breaking technologies such as our zinc finger protein platform for therapeutic applications with the potential to fundamentally change the way medicine is practiced," said H. Stewart Parker, Sangamo director and nominee to succeed Lanphier as board chair following the Annual Meeting.

  • PR Newswireyesterday

    Sangamo Therapeutics Announces Presentations at 2017 Annual meeting of the American Society of Gene & Cell Therapy

    RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced that data from the Company's therapeutic and research programs ...

  • PR Newswireyesterday

    Sangamo Therapeutics Announces Participation In The ARM 5th Annual Cell & Gene Therapy Investor Day

    RICHMOND, Calif., April 24, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, announced today that Dr. Sandy Macrae, Sangamo's chief executive officer, ...